

(Code:4188)
June 15, 2021

To Shareholders:

Yoshimitsu Kobayashi
Director of the Board, Chairperson
1-1 Marunouchi 1-chome, Chiyoda-ku, Tokyo
Mitsubishi Chemical Holdings Corporation

Partial Revisions in "Notice of the 16th Ordinary General Meeting of Shareholders"

There were mistakes in part of some items included in "Notice of the 16th Ordinary General Meeting of Shareholders" of which we posted on our website dated May 26, 2021. As such, in addition to expressing our sincerely apologizes, the contents will be revised as follows (the revised parts are underlined).

Please note that the revised version has already been posted on our website.

(1) Notice of the 16th Ordinary General Meeting of Shareholders' page 12

The following description of "Position and duty at the Company" for Ken Fujiwara, a candidate for Director of the Board

(Before revision)

Position and duty at the Company	Director of the Board, Managing Corporate Executive Officer (Corporate <u>Governance</u> , Legal, Administration and Human Resources, Internal Control, Overseas Administration Headquarters) Chief Group Compliance Officer Member of the Compensation Committee
----------------------------------	---

(After revision)

Position and duty at the Company	Director of the Board, Managing Corporate Executive Officer (Corporate <u>Secretary</u> , Legal, Administration and Human Resources, Internal Control, Overseas Administration Headquarters) Chief Group Compliance Officer Member of the Compensation Committee
----------------------------------	--

(2) Notice of the 16th Ordinary General Meeting of Shareholders' page 46

The following description of "Details of Corporate Executive Officers (as of April 1, 2021)"

(Before revision)

Ken Fujiwara	Managing Corporate Executive Officer Chief Group Compliance Officer	Corporate Governance, Legal, Administration and Human Resources, Internal Control, and Overseas Administration Headquarters	Director of Mitsubishi Tanabe Pharma Corporation Director of Mitsubishi Chemical Holdings (Beijing) Co., Ltd.
--------------	--	---	--

(After revision)

Ken Fujiwara	Managing Corporate Executive Officer Chief Group Compliance Officer	Corporate Secretary , Legal, Administration and Human Resources, Internal Control, and Overseas Administration Headquarters	Director of Mitsubishi Tanabe Pharma Corporation Director of Mitsubishi Chemical Holdings (Beijing) Co., Ltd.
--------------	--	--	--

(3) Notice of the 16th Ordinary General Meeting of Shareholders' page 85

The following description of "1. Impairment of non-financial assets (1) Amount recorded in the consolidated financial statements for the fiscal year under review"

(Before revision)

For the fiscal year under review, an impairment loss of ¥118,291 million was recorded and included under other expenses in the consolidated statement of profit or loss.

(After revision)

For the fiscal year under review, an impairment loss of ¥127,193 million was recorded and included under other expenses in the consolidated statement of profit or loss.

(4) Notice of the 16th Ordinary General Meeting of Shareholders' page 86

The following description of "4. Fair value of financial instruments (1) Amount recorded in the consolidated financial statements for the fiscal year under review"

(Before revision)

Equity securities and investments (excluding assets measured at fair value based on unadjusted published prices in active markets for identical assets or liabilities): ¥137,592 million

(After revision)

Equity securities and investments (excluding assets measured at fair value based on unadjusted published prices in active markets for identical assets or liabilities): ¥133,322 million